219 related articles for article (PubMed ID: 26402249)
1. Pancreatic cancer: BRCA mutation and personalized treatment.
Luo G; Lu Y; Jin K; Cheng H; Guo M; Liu Z; Long J; Liu C; Ni Q; Yu X
Expert Rev Anticancer Ther; 2015; 15(10):1223-31. PubMed ID: 26402249
[TBL] [Abstract][Full Text] [Related]
2. BRCA and pancreatic cancer.
Brennan GT; Relias V; Saif MW
JOP; 2013 Jul; 14(4):325-8. PubMed ID: 23846919
[TBL] [Abstract][Full Text] [Related]
3. Recapitulating the clinical scenario of BRCA-associated pancreatic cancer in pre-clinical models.
Golan T; Stossel C; Atias D; Buzhor E; Halperin S; Cohen K; Raitses-Gurevich M; Glick Y; Raskin S; Yehuda D; Feldman A; Schvimer M; Friedman E; Karni R; Wilson JM; Denroche RE; Lungu I; Bartlett JMS; Mbabaali F; Gallinger S; Berger R
Int J Cancer; 2018 Jul; 143(1):179-183. PubMed ID: 29396858
[TBL] [Abstract][Full Text] [Related]
4. PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies.
Lee JM; Ledermann JA; Kohn EC
Ann Oncol; 2014 Jan; 25(1):32-40. PubMed ID: 24225019
[TBL] [Abstract][Full Text] [Related]
5.
Rosen MN; Goodwin RA; Vickers MM
World J Gastroenterol; 2021 May; 27(17):1943-1958. PubMed ID: 34007132
[TBL] [Abstract][Full Text] [Related]
6. PARP-inhibitors in BRCA-associated pancreatic cancer.
Bhalla A; Saif MW
JOP; 2014 Jul; 15(4):340-3. PubMed ID: 25076338
[TBL] [Abstract][Full Text] [Related]
7. PARP inhibitors: shifting the paradigm in the treatment of pancreatic cancer.
Desai D; Khandwala P; Parsi M; Potdar R
Med Oncol; 2021 Apr; 38(6):61. PubMed ID: 33891252
[TBL] [Abstract][Full Text] [Related]
8. The role of PARP inhibitors in germline BRCA-associated pancreatic ductal adenocarcinoma.
Moffat GT; O'Reilly EM
Clin Adv Hematol Oncol; 2020 Mar; 18(3):168-179. PubMed ID: 32609666
[TBL] [Abstract][Full Text] [Related]
9. Importance of
Martínez-Galán J; Rodriguez I; Caba O
World J Gastroenterol; 2021 Oct; 27(39):6515-6521. PubMed ID: 34754149
[TBL] [Abstract][Full Text] [Related]
10. Pancreas cancer and BRCA: A critical subset of patients with improving therapeutic outcomes.
Momtaz P; O'Connor CA; Chou JF; Capanu M; Park W; Bandlamudi C; Berger MF; Kelsen DP; Suehnholz SP; Chakravarty D; Yu KH; Varghese AM; Zervoudakis A; Li J; Ku GY; Park JS; Shcherba M; Harding JJ; Goldberg Z; Abou-Alfa GK; Salo-Mullen EE; Stadler ZK; Iacobuzio-Donahue CA; O'Reilly EM
Cancer; 2021 Dec; 127(23):4393-4402. PubMed ID: 34351646
[TBL] [Abstract][Full Text] [Related]
11. Breast cancer in BRCA mutation carriers: medical treatment.
Milani A; Geuna E; Zucchini G; Aversa C; Martinello R; Montemurro F
Minerva Ginecol; 2016 Oct; 68(5):557-65. PubMed ID: 26799758
[TBL] [Abstract][Full Text] [Related]
12. DNA Damage Repair and the Emerging Role of Poly(ADP-ribose) Polymerase Inhibition in Cancer Therapeutics.
Rabenau K; Hofstatter E
Clin Ther; 2016 Jul; 38(7):1577-88. PubMed ID: 27368114
[TBL] [Abstract][Full Text] [Related]
13. A meta-analysis of reversion mutations in BRCA genes identifies signatures of DNA end-joining repair mechanisms driving therapy resistance.
Tobalina L; Armenia J; Irving E; O'Connor MJ; Forment JV
Ann Oncol; 2021 Jan; 32(1):103-112. PubMed ID: 33091561
[TBL] [Abstract][Full Text] [Related]
14. On the road to PARPi-platin.
Bookman MA
J Natl Cancer Inst; 2014 Jun; 106(6):dju119. PubMed ID: 24842884
[No Abstract] [Full Text] [Related]
15. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
Oza AM; Cibula D; Benzaquen AO; Poole C; Mathijssen RH; Sonke GS; Colombo N; Špaček J; Vuylsteke P; Hirte H; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Lowe ES; Dougherty B; Barrett JC; Friedlander M
Lancet Oncol; 2015 Jan; 16(1):87-97. PubMed ID: 25481791
[TBL] [Abstract][Full Text] [Related]
16. Molecular pathways: how can BRCA-mutated tumors become resistant to PARP inhibitors?
Bouwman P; Jonkers J
Clin Cancer Res; 2014 Feb; 20(3):540-7. PubMed ID: 24270682
[TBL] [Abstract][Full Text] [Related]
17. Germline BRCA Mutations in a Large Clinic-Based Cohort of Patients With Pancreatic Adenocarcinoma.
Holter S; Borgida A; Dodd A; Grant R; Semotiuk K; Hedley D; Dhani N; Narod S; Akbari M; Moore M; Gallinger S
J Clin Oncol; 2015 Oct; 33(28):3124-9. PubMed ID: 25940717
[TBL] [Abstract][Full Text] [Related]
18. The Clinical Implications of Reversions in Patients with Advanced Pancreatic Cancer and Pathogenic Variants in BRCA1, BRCA2, or PALB2 after Progression on Rucaparib.
Brown TJ; Yablonovitch A; Till JE; Yen J; Kiedrowski LA; Hood R; O'Hara MH; Teitelbaum U; Karasic TB; Schneider C; Carpenter EL; Nathanson K; Domchek SM; Reiss KA
Clin Cancer Res; 2023 Dec; 29(24):5207-5216. PubMed ID: 37486343
[TBL] [Abstract][Full Text] [Related]
19. Murine models for familial pancreatic cancer: Histopathology, latency and drug sensitivity among cancers of Palb2, Brca1 and Brca2 mutant mouse strains.
Park D; Shakya R; Koivisto C; Pitarresi JR; Szabolcs M; Kladney R; Hadjis A; Mace TA; Ludwig T
PLoS One; 2019; 14(12):e0226714. PubMed ID: 31877165
[TBL] [Abstract][Full Text] [Related]
20. Predominant Ashkenazi BRCA1/2 mutations in families with pancreatic cancer.
Dagan E
Genet Test; 2008 Jun; 12(2):267-71. PubMed ID: 18439109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
